# Phase II Combination Steroid and Anti-VEGF for Persistent DME

> **NCT01945866** · PHASE2 · COMPLETED · sponsor: **Jaeb Center for Health Research** · enrollment: 129 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** intravitreal ranibizumab 0.3 mg
- **DRUG:** dexamethasone intravitreal implant
- **PROCEDURE:** Sham injection

## Key facts

- **NCT ID:** NCT01945866
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2017-06-05
- **Final completion:** 2017-06-05
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2018-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01945866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01945866, "Phase II Combination Steroid and Anti-VEGF for Persistent DME". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01945866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*